Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials

By afschroeder • July 23, 2026

Hageen AW, Gadelmawla AF, Saleh AO, Mohamed MR, Abdallfatah A, Elsekhary A, El-Nemr AF, Eladawi S, Maihoub O, Abdulhay H, Turkmani M, Abdelazeem B, Fonarow GC. Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials. Endocrinol Diabetes Metab. 2026 Jul;9(4):e70275. doi: 10.1002/edm2.70275. PMID: 42487237.

Tags: body weight, Cardiology/Epi, glucagon‐like peptide‐1 receptor agonists, HbA1c, Obesity, orforglipron, Publications

Association of care fragmentation with financial and clinical outcomes of transcatheter aortic valve replacement in the US: A retrospective cohort study

Chaturvedi A, Mallick S, Le NK, Tabibian K, Balian J, Yalzadeh D, Badiee B, Zinoviev R, Benharash P. Association of care fragmentation with financial and[...]

Loss of ATP-Dependent Citrate Lyase Drives Left Ventricular Dysfunction by Metabolic Remodeling

Liu S, Gammon ST, Tan L, Gao Y, Kim K, Elbatreek MH, Arrieta A, Williamson IK, Salazar RL, Pham J, Davidian A, Khanna Neicheril R,[...]

Dashboard-Directed Intervention to Improve Guideline-Directed Heart Failure Therapy for Veterans

Sheng Q, Brownell NK, Hsu JJ, Chang DS, Fonarow GC, Ziaeian B. Dashboard-Directed Intervention to Improve Guideline-Directed Heart Failure Therapy for Veterans. JACC Adv. 2026[...]